<!doctype html><html lang=cn><head><meta charset=utf-8><meta http-equiv=x-ua-compatible content="IE=edge"><meta name=viewport content="width=device-width,initial-scale=1"><meta name=referrer content="no-referrer"><link rel=dns-prefetch href=https://i.geekbank.cf/><title>2019 AACR | Kè¯åœ¨å¹¿æ³›æœŸSCLCæ‚£è€…ä¸­æ˜¾ç¤ºå‡ºä»¤äººé¼“èˆçš„æŠ—è‚¿ç˜¤æ´»æ€§å’ŒæŒä¹…ååº” | æå®¢å¿«è¨Š</title><meta property="og:title" content="2019 AACR | Kè¯åœ¨å¹¿æ³›æœŸSCLCæ‚£è€…ä¸­æ˜¾ç¤ºå‡ºä»¤äººé¼“èˆçš„æŠ—è‚¿ç˜¤æ´»æ€§å’ŒæŒä¹…ååº” - æå®¢å¿«è¨Š"><meta property="og:type" content="article"><meta property="og:locale" content="cn"><meta property="og:image" content="https://p3.pstatp.com/large/pgc-image/RMO1D3wIM6bQ5S"><link rel=alternate hreflang=x-default href=https://geekbank.cf/tw/%e7%a7%91%e6%8a%80/8cb2a5eb.html><link rel=alternate hreflang=zh-tw href=https://geekbank.cf/tw/%e7%a7%91%e6%8a%80/8cb2a5eb.html><link rel=alternate hreflang=zh-cn href=https://geekbank.cf/cn/%e7%a7%91%e6%8a%80/8cb2a5eb.html><link rel=alternate hreflang=zh-hk href=https://geekbank.cf/tw/%e7%a7%91%e6%8a%80/8cb2a5eb.html><link rel=alternate hreflang=zh-mo href=https://geekbank.cf/tw/%e7%a7%91%e6%8a%80/8cb2a5eb.html><link rel=alternate hreflang=zh-my href=https://geekbank.cf/cn/%e7%a7%91%e6%8a%80/8cb2a5eb.html><link rel=alternate hreflang=zh-sg href=https://geekbank.cf/cn/%e7%a7%91%e6%8a%80/8cb2a5eb.html><link rel=canonical href=https://geekbank.cf/tw/%e7%a7%91%e6%8a%80/8cb2a5eb.html><meta property="article:published_time" content="2020-11-14T21:02:05+08:00"><meta property="article:modified_time" content="2020-11-14T21:02:05+08:00"><meta name=Keywords content><meta name=description content="2019 AACR | Kè¯åœ¨å¹¿æ³›æœŸSCLCæ‚£è€…ä¸­æ˜¾ç¤ºå‡ºä»¤äººé¼“èˆçš„æŠ—è‚¿ç˜¤æ´»æ€§å’ŒæŒä¹…ååº”"><meta name=author content="æå®¢å¿«è¨Š"><meta property="og:url" content="/cn/%E7%A7%91%E6%8A%80/8cb2a5eb.html"><link rel=apple-touch-icon sizes=180x180 href=../../apple-touch-icon.png><link rel=icon type=image/png sizes=32x32 href=../../favicon-32x32.png><link rel=icon type=image/png sizes=16x16 href=../../favicon-16x16.png><link rel=manifest href=../../site.webmanifest><link rel=mask-icon href=../../safari-pinned-tab.svg color=#5bbad5><meta name=msapplication-TileColor content="#ffc40d"><meta name=theme-color content="#ffffff"><link rel=stylesheet href=https://geekbank.cf/css/normalize.css><link rel=stylesheet href=https://geekbank.cf/css/style.css><script type=text/javascript src=https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js></script><script type=text/javascript src=https://geekbank.cf/js/jqthumb.min.js></script><script data-ad-client=ca-pub-3525055026201463 async src=https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js></script></head><body><header id=header class=clearfix><div class=container><div class=col-group><div class=site-name><h1><a id=logo href>ğŸ¤“ æå®¢å¿«è®¯ Geek Bank</a></h1><p class=description>ä¸ºä½ å¸¦æ¥æœ€å…¨çš„ç§‘æŠ€çŸ¥è¯† ğŸ§¡</p></div><div><nav id=nav-menu class=clearfix><a class=current href>çŒœä½ å–œæ­¡</a>
<a href=../../tw/categories/%E7%A7%91%E6%8A%80.html title=ç§‘æŠ€>ç§‘æŠ€</a>
<a href=../../tw/categories/%E9%81%8A%E6%88%B2.html title=éŠæˆ²>éŠæˆ²</a>
<a href=../../tw/categories/%E7%A7%91%E5%AD%B8.html title=ç§‘å­¸>ç§‘å­¸</a></nav></div></div></div></header><div id=body><div class=container><div class=col-group><div class=col-8 id=main><div class=res-cons><article class=post><header><h1 class=post-title>2019 AACR | Kè¯åœ¨å¹¿æ³›æœŸSCLCæ‚£è€…ä¸­æ˜¾ç¤ºå‡ºä»¤äººé¼“èˆçš„æŠ—è‚¿ç˜¤æ´»æ€§å’ŒæŒä¹…ååº”</h1></header><date class="post-meta meta-date">2020-11-14</date><div class=post-meta><span>|</span>
<span class=meta-category><a href=cn/categories/%E7%A7%91%E6%8A%80.html>ç§‘æŠ€</a></span></div><div class=post-content><img alt="2019 AACR | Kè¯åœ¨å¹¿æ³›æœŸSCLCæ‚£è€…ä¸­æ˜¾ç¤ºå‡ºä»¤äººé¼“èˆçš„æŠ—è‚¿ç˜¤æ´»æ€§å’ŒæŒä¹…ååº”" onerror=errorimg.call(this); src=https://p3.pstatp.com/large/pgc-image/RMO1D3wIM6bQ5S><p>2019å¹´ç¾å›½ç™Œç—‡ç ”ç©¶åä¼š(AACR)å¹´ä¼šäº2019å¹´3æœˆ29æ—¥â€”4æœˆ3æ—¥åœ¨ç¾å›½äºšç‰¹å…°å¤§ä¸¾è¡Œã€‚AACRå¹´ä¼šæ˜¯ä¸–ç•Œä¸Šè§„æ¨¡æœ€å¤§çš„ç™Œç—‡ç ”ç©¶ä¼šè®®ä¹‹ä¸€ï¼Œä»Šå¹´AACRå¤§ä¼šä¸»é¢˜ä¸ºâ€œç»¼åˆæ€§ç™Œç—‡ç§‘å­¦â€¢å…¨çƒå½±å“â€¢ä¸ªæ€§åŒ–æ‚£è€…æŠ¤ç†â€ã€‚å…ç–«ç–—æ³•ä¾æ—§æ˜¯ä»Šå¹´AACRçš„ä¸€ä¸ªé‡è¦ä¸»é¢˜ã€‚</p><p>3æœˆ28æ—¥ï¼Œå¸•åšåˆ©ç å•æŠ—ï¼ˆKè¯ï¼‰ä¸€çº¿æ²»ç–—è½¬ç§»æ€§éé³çŠ¶éå°ç»†èƒè‚ºç™Œï¼ˆNSCLCï¼‰çš„é€‚åº”è¯æ­£å¼è·æ‰¹ã€‚è¿™ä¸€é‡ç£…æ¶ˆæ¯çš„ä½™çƒ­è¿˜æœªæ•£å»ï¼Œå¸•åšåˆ©ç å•æŠ—çš„åˆä¸€åˆ©å¥½æ¶ˆæ¯åœ¨2019å¹´çš„AACRå¹´ä¼šä¸Šè¢«å…¬å¸ƒã€‚</p><p>ç¾å›½å½“åœ°æ—¶é—´4æœˆ1æ—¥åˆé—´ï¼ŒéŸ©å›½å»¶ä¸–å¤§å­¦åŒ»å­¦é™¢å»¶ä¸–ç™Œç—‡ä¸­å¿ƒHyun Cheol Chungæ•™æˆå…¬å¸ƒäº†KEYNOTE-028å’ŒKEYNOTE-158è¯•éªŒçš„æ±‡æ€»åˆ†æï¼Œåˆ†æç»“æœæ˜¾ç¤ºï¼Œå¸•åšåˆ©ç å•æŠ—åœ¨é¢„å¤„ç†çš„æ™šæœŸå°ç»†èƒè‚ºç™Œï¼ˆSCLCï¼‰æ‚£è€…ä¸­è¡¨ç°å‡ºä»¤äººé¼“èˆçš„æŠ—è‚¿ç˜¤æ´»æ€§å’ŒæŒä¹…ååº”ã€‚</p><p><strong>ç ”ç©¶æ–¹æ³•</strong></p><p>è¯¥æ±‡æ€»åˆ†æä»…å…³æ³¨KEYNOTE-028è¯•éªŒä¸­çš„IbæœŸå’ŒKEYNOTE-158ä¸­çš„IIæœŸè¯•éªŒçš„SCLCé˜Ÿåˆ—ï¼Œå¹¶å¯¹ç¬¦åˆçº³å…¥åˆ†æè¦æ±‚çš„æ‚£è€…è¿›è¡Œäº†ç»„ç»‡å­¦æˆ–ç»†èƒå­¦è¯å®ï¼Œä¿è¯å…¶æ»¡è¶³æ— æ³•æ²»æ„ˆçš„æ™šæœŸSCLCï¼Œæ ‡å‡†æ²»ç–—è¿›å±•æˆ–å¤±è´¥ï¼Œä¸”æœªæ¥å—å…ç–«æ²»ç–—çš„æ¡ä»¶ã€‚</p><p>ä¸¤é¡¹è¯•éªŒå…±çº³å…¥131ä¾‹SCLCæ‚£è€…ï¼ŒåŒ…æ‹¬æ¥è‡ªKEYNOTE-028çš„24åæ‚£è€…å’Œæ¥è‡ªKEYNOTE-158çš„107åæ‚£è€…ã€‚å…¶ä¸­ï¼Œ83åæ¥å—è¿‡â‰¥2æ¬¡æ²»ç–—çš„æ‚£è€…è¢«ç¡®å®šæœ‰èµ„æ ¼è¿›è¡Œç–—æ•ˆåˆ†æã€‚è™½ç„¶å‚åŠ KEYNOTE-028è¯•éªŒçš„æ‚£è€…éœ€è¦æ‚£æœ‰PD-L1é˜³æ€§è‚¿ç˜¤ï¼ˆç»¼åˆé˜³æ€§è¯„åˆ†â‰¥1ï¼‰ï¼Œä½†è¿™ä¸æ˜¯ç™»è®°KEYNOTE-158æ‰€å¿…éœ€çš„ã€‚</p><p>åœ¨KEYNOTE-028ä¸­æ¯8å‘¨è¿›è¡Œä¸€æ¬¡æ”¾å°„æˆåƒï¼ŒKEYNOTE-158ä¸­åˆ™æ¯9å‘¨è¿›è¡Œä¸€æ¬¡ï¼›KEYNOTE-028ä¸­6ä¸ªæœˆåæ¯12å‘¨è¿›è¡Œä¸€æ¬¡ï¼ŒKEYNOTE-158ä¸­åˆ™åœ¨è¿›è¡Œ1å¹´åå†æ”¹ä¸ºæ¯12å‘¨ä¸€æ¬¡ã€‚è¯•å‰‚çš„å‰‚é‡åœ¨ä¸¤é¡¹è¯•éªŒä¸­ä¹Ÿå­˜åœ¨å·®åˆ«ã€‚åœ¨KEYNOTE-028ä¸­æ¯2å‘¨ç»™äºˆå¸•åšåˆ©ç å•æŠ— 10mg / kgï¼Œè€Œåœ¨KEYNOTE-158ä¸­åˆ™æ˜¯æ¯3å‘¨ç»™äºˆ200mgå‰‚é‡ã€‚ç»™è¯å‰‚æŒç»­2å¹´æˆ–ç›´è‡³ç–¾ç—…è¿›å±•æˆ–æ¯’æ€§ä¸èƒ½è€å—åˆ™ç»ˆæ­¢ã€‚</p><p>ä¸¤é¡¹ç ”ç©¶çš„ä¸»è¦ç»ˆç‚¹æ˜¯ç›¸åŒçš„ï¼šæ€»ç¼“è§£ç‡ï¼ˆORRï¼‰ï¼Œæ ¹æ®RECIST 1.1æ ‡å‡†è¯„ä¼°ã€‚ç¼“è§£æŒç»­æ—¶é—´ï¼ˆDORï¼‰ï¼Œæ— è¿›å±•ç”Ÿå­˜æœŸï¼ˆPFSï¼‰å’Œæ€»ç”Ÿå­˜æœŸï¼ˆOSï¼‰å‡ä½œä¸ºæ¬¡è¦ç»ˆç‚¹ï¼Œå¹¶ä¸”ä½¿ç”¨Kaplan-Meieræ–¹æ³•è¿›è¡Œä¼°è®¡ã€‚</p><p><strong>ç ”ç©¶ç»“æœ</strong></p><p>æ¥è‡ªKEYNOTE-028çš„æ•°æ®æ˜¾ç¤ºORRä¸º33.3%ï¼ˆ95%CIï¼Œ15.6%-55.3%ï¼‰å’ŒDORä¸º19.4ä¸ªæœˆï¼ˆ3.6 +è‡³20.0+ï¼‰ã€‚å°±ç”Ÿå­˜è·ç›Šè€Œè¨€ï¼Œä½¿ç”¨å¸•åšåˆ©ç å•æŠ—æ²»ç–—åï¼Œæ‚£è€…çš„ä¸­ä½PFSä¸º1.9ä¸ªæœˆï¼ˆ95%CIï¼Œ1.7-5.9ï¼‰ï¼Œä¸­ä½OSä¸º9.7ä¸ªæœˆï¼ˆ95%CIï¼Œ4.1-æœªè¾¾åˆ°ï¼‰ã€‚ç›¸æ¯”ä¹‹ä¸‹ï¼Œåœ¨IIæœŸKEYNOTE-158è¯•éªŒä¸­ç”¨PD-1æŠ‘åˆ¶å‰‚è§‚å¯Ÿåˆ°çš„ORRä¸º18.7%ï¼ˆ95%CIï¼Œ11.8%-27.4%ï¼‰ï¼Œè€ŒDORå°šæœªè¾¾åˆ°ï¼ˆ2.1+è‡³18.7+ï¼‰ã€‚è¯¥è¯•éªŒçš„ä¸­ä½PFSå’ŒOSåˆ†åˆ«ä¸º2.0ä¸ªæœˆï¼ˆ95%CIï¼Œ1.9-2.1ï¼‰å’Œ8.7ä¸ªæœˆï¼ˆ95%CIï¼Œ5.6-12.0ï¼‰ã€‚</p><p>æ±‡æ€»åˆ†æç»“æœæ˜¾ç¤ºï¼ŒORRä¸º19.3%ï¼ˆ16ä¾‹æ‚£è€…ï¼›95%CIï¼Œ11.4%-29.4%ï¼‰ï¼Œå…¶ä¸­2ä¾‹æ‚£è€…ï¼ˆ2%ï¼‰è¾¾åˆ°å®Œå…¨ç¼“è§£ï¼Œ14ä¾‹æ‚£è€…ï¼ˆ17%ï¼‰éƒ¨åˆ†ç¼“è§£ï¼Œ15ä¾‹æ‚£è€…ç—…æƒ…ç¨³å®šï¼ˆ18%ï¼‰ã€‚9åå—è®¿è€…ï¼ˆ61%ï¼‰çš„DORâ‰¥18ä¸ªæœˆã€‚</p><p>ä¸­ä½éšè®¿æ—¶é—´ä¸º7.7ä¸ªæœˆï¼ˆ0.5-48.7ï¼‰ï¼Œç ”ç©¶è€…è§‚å¯Ÿåˆ°ä¸­ä½PFSä¸º2ä¸ªæœˆï¼ˆ95%CIï¼Œ1.9-3.4ï¼‰ï¼Œä¸­ä½OSä¸º7.7ä¸ªæœˆï¼ˆ95%CIï¼Œ5.2-10.1ï¼‰ã€‚åœ¨12ä¸ªæœˆçš„éšè®¿ä¸­ï¼ŒPFSç‡ä¸º17%ï¼Œè€ŒOSç‡ä¸º34%ï¼›åœ¨24ä¸ªæœˆæ—¶ï¼ŒPFSå’ŒOSç‡åˆ†åˆ«ä¸º13%å’Œ21%ã€‚</p><p>å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œ16åç¼“è§£è€…ä¸­æœ‰14åPD-L1é˜³æ€§ã€‚ç”±äºä¸¤é¡¹è¯•éªŒæœ‰ä¸åŒçš„è¯„ä¼°PD-L1çš„æ–¹æ³•ï¼Œå‚ä¸æ±‡æ€»åˆ†æçš„ç ”ç©¶è€…å¹¶ä¸æ‰“ç®—è¯„ä¼°PD-L1é˜³æ€§åœ¨æ‚£è€…é€‰æ‹©ä¸­çš„ä½œç”¨ã€‚</p><p>åœ¨åˆ†æä¸­è§‚å¯Ÿåˆ°ä¸è‰¯äº‹ä»¶ï¼ˆAEï¼‰ä¸å…ˆå‰å…³äºæŠ—PD-1å•å…‹éš†æŠ—ä½“çš„å®‰å…¨æ€§ç‰¹å¾çš„æŠ¥é“ä¸€è‡´ã€‚åœ¨KEYNOTE-028å’ŒKEYNOTE-158ä¸¤é¡¹è¯•éªŒçš„æ‰€æœ‰SCLCæ‚£è€…ï¼ˆN = 131ï¼‰ä¸­ï¼Œä¸è€ƒè™‘å…ˆå‰çš„æ²»ç–—ï¼Œ8%å‡ºç°3çº§æ²»ç–—ç›¸å…³çš„AEï¼ˆæ²¡æœ‰4çº§æ²»ç–—ç›¸å…³çš„AEï¼‰ï¼Œ3åæ‚£è€…å‡ºç°5çº§æ²»ç–—ç›¸å…³çš„AEï¼ˆè‚ ç¼ºè¡€ã€è‚ºç‚ã€è„‘ç—…ï¼‰ã€‚21%çš„æ‚£è€…ç»å†è¿‡å…ç–«ä»‹å¯¼çš„AEæˆ–è¾“æ³¨ååº”ã€‚</p><p><strong>ç»“è®º</strong></p><p>å¸•åšåˆ©ç å•æŠ—åœ¨æ¥å—è¿‡ä¸¤æ¬¡æˆ–æ›´å¤šæ¬¡æ²»ç–—çš„å¹¿æ³›æœŸSCLCæ‚£è€…ä¸­æ˜¾ç¤ºå‡ºä»¤äººé¼“èˆçš„æŠ—è‚¿ç˜¤æ´»æ€§ï¼Œä¸”ååº”æŒä¹…ï¼Œå¤§å¤šæ•°æ‚£è€…çš„ç¼“è§£æŒç»­æ—¶é—´è‡³å°‘ä¸º18ä¸ªæœˆï¼Œå¹¶æ²¡æœ‰è§‚å¯Ÿåˆ°å¸•åšåˆ©ç å•æŠ—é¢„æœŸä»¥å¤–çš„æ¯’æ€§ã€‚</p><p><strong>è‹±æ–‡æ‘˜è¦</strong></p><p><strong>Background: </strong>The antitumor activity of the anti-PD-1 monoclonal antibody pembrolizumab in patients with advanced SCLC has been evaluated in the Phase Ib basket study KEYNOTE-028 (KN028; NCT02054806) and in the Phase II basket study KEYNOTE-158 (KN158; NCT02628067). We present outcomes for patients enrolled in KN028 and KN158 who were receiving pembrolizumab after â‰¥2 lines of prior therapy.</p><p><strong>Methods:</strong>Eligible patients had histologically/cytologically confirmed incurable advanced SCLC, measurable disease per RECIST 1.1, ECOG PS of 0/1, had experienced progression/failure on standard therapy, and were immunotherapy-naive; patients included in this analysis had received â‰¥2 lines of systemic therapy. Patients in KN028 were required to have PD-L1-positive tumors (membranous PD-L1 expression in â‰¥1% of tumor and associated inflammatory cells or positive staining in stroma); tumor PD-L1 expression was not required in KN158. Radiographic imaging was performed Q8W for 6 mo (KN028) or Q9W for 1 y (KN158), and Q12W thereafter. Pembrolizumab (10 mg/kg Q2W [KN028] or 200 mg Q3W [KN158]) was administered for 2 y or until disease progression or intolerable toxicity. The primary endpoint in both studies was objective response rate (ORR) assessed per RECIST 1.1. Duration of response (DOR), progression-free survival (PFS), and overall survival (OS) were secondary endpoints and estimated using the Kaplan-Meier method. For this analysis, assessment of response was by independent central review.</p><p><strong>Results:</strong>Of 131 SCLC pts included in both trials, 83 were eligible for efficacy analyses (KN158, n=64; KN028, n=19). Median age was 62 (range, 24â€’84) y, 64% were men, and 36% had received â‰¥3 lines of systemic therapy. As of the data cutoff date, median follow-up was 7.7 (range, 0.5â€’48.7) mo. The ORR was 19.3% (95% CI, 11.4-29.4). Two patients had a complete response and 14 had a partial response per independent central review; 14 of 16 responders were PD-L1-positive. Median DOR was not reached (range, 4.1-35.8 [ongoing] mo). 9 of 16 responders (61% per Kaplan-Meier estimate) had response lasting â‰¥18 mo. Median PFS was 2.0 (95% CI, 1.9-3.4) mo and median OS was 7.7 (95% CI, 5.2-10.1) mo. 12- and 24-month rates were 16.9% and 13.1% for PFS, and 34% and 21% for OS. Among all SCLC patients in KN028 and KN158 irrespective of prior therapies (N=131), 8% had a grade 3 treatment-related AE (no grade 4 treatment-related AEs). 3 patients had grade 5 treatment-related AEs (intestinal ischemia, pneumonia, encephalopathy). 21% experienced an immune-mediated AE or infusion reaction.</p><p><strong>Conclusions: </strong>Pembrolizumab demonstrated promising antitumor activity in patients with advanced SCLC who had received â‰¥2 lines of prior therapy. Responses were durable, with the majority of patients estimated to have a response duration of at least 18 mo. No unexpected toxicities from pembrolizumab were observed.</p><p>å‚è€ƒæ¥æºï¼š</p><p>[1] Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies. Abstract CT073</p><p>[2] Pembrolizumab Shows Promising Antitumor Activity in Pretreated Patients with SCLC. Onclive/Conference-coverage/AACR-2019.Tuesday, Apr 02, 2019</p><p>2019 AACR ä¸“é¢˜</p><p>é•¿æŒ‰è¯†åˆ«äºŒç»´ç æŸ¥çœ‹</p></div><div class="post-meta meta-tags"><ul class=clearfix><li><a>'2019','AACR','è¯åœ¨'</a></li></ul></div></article></div></div><div id=secondary><section class=widget><form id=search action=//www.google.com/search method=get accept-charset=utf-8 target=_blank _lpchecked=1><input type=text name=q maxlength=20 placeholder=æœç´¢>
<input type=hidden name=sitesearch value=geekbank.cf>
<button type=submit>ğŸ”</button></form></section><section class=widget><h3 class=widget-title>æœ€æ–°æ–‡ç«  âš¡</h3><ul class=widget-list></ul></section><section class=widget><h3 class=widget-title>å…¶ä»–</h3><ul class=widget-list><li><a href=TOS.html>ä½¿ç”¨æ¢æ¬¾</a></li><li><a href=CommentPolicy.html>ç•™è¨€æ”¿ç­–</a></li><li><a href=mailto:gdnews@tuta.io rel=nofollow>DMCA</a></li><li><a href=mailto:gdnews@tuta.io rel=nofollow>è¯çµ¡æˆ‘å€‘</a></li></ul></section></div></div></div></div><footer id=footer><div class=container>&copy; 2020 <a href>æå®¢å¿«è¨Š</a></div></footer><script type=text/javascript>window.MathJax={tex2jax:{inlineMath:[['$','$']],processEscapes:true}};</script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js?config=TeX-MML-AM_CHTML" async></script><a id=rocket href=#top></a><script type=text/javascript src=https://kknews.cf/js/totop.js async></script><script type=application/javascript>var doNotTrack=false;if(!doNotTrack){window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)};ga.l=+new Date;ga('create','UA-146415161-2','auto');ga('send','pageview');}</script><script async src=https://www.google-analytics.com/analytics.js></script><script type=text/javascript src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-5e508ed9e4e698bb"></script></body></html>